Experience

Davis Polk advised the underwriters in connection with a secondary offering of 7,500,000 shares of Class A common stock of Evolent Health, Inc. by certain of Evolent’s existing stockholders…

Davis Polk advised the joint lead dealer managers in connection with the registered offers by Abbott Laboratories to exchange certain outstanding debt securities of St. Jude Medical,…

Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 1,495,000 shares of common stock for an aggregate price to the public of approximately $113.62 million…

Davis Polk advised the active joint book-running managers and representatives of the underwriters in connection with the $90 million follow-on offering of 4,000,000 shares of common stock…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which Valeant issued new debt to refinance its shorter term…

Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public debt offering by Bristol-Myers Squibb Company of $750 million…

Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000,000 warrants, each warrant entitling its holder to purchase 0.7…

Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling shareholder of 40,171,429 common shares for an aggregate amount of…

Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of Coherus BioSciences, Inc. The common stock is listed on the NASDAQ…

Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes issued by Change Healthcare Holdings, LLC and Change Healthcare…